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Please note: 
Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications and conference abstracts of 
phase III trials, assessing the safety and efficacy of the drugs of interest. 
At the very end of each chapter we have provided a table containing the prioritization criteria and a 
drop-down field to apply the provided criteria. 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 30 prioritisation (February 2017), 12 drugs were filteredout of 301 identified and were sent 
to prioritisation. Of these, 5 drugs were ranked as ‘highly relevant’ by the expert panel, 7 as 
‘relevant’ and 0 as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for 
example, abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
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1. Atezolizumab (Tecentriq®) versus docetaxel in patients with previously treated non-
small-cell lung cancer 
Highly 
relevant 
2. Cabozantinib (Cabometyx®) versus sunitinib as initial targeted therapy for patients with 
metastatic renal cell carcinoma of poor or intermediate risk Relevant 
3. Nivolumab (Opdivo®) in metastatic urothelial carcinoma after platinum therapy Relevant 
4. Pembrolizumab (Keytruda®, MK-3475) as second-line therapy for advanced urothelial 
carcinomas 
Highly 
relevant 
5. Daratumumab (Darzalex®), bortezomib, and dexamethasone for multiple myeloma Highly 
relevant 
6. 
Bortezomib (Velcade®) with lenalidomide and dexamethasone versus lenalidomide and 
dexamethasone alone in patients with newly diagnosed myeloma without intent for 
immediate autologous stem-cell transplant 
Highly 
relevant 
7. 
Trastuzumab emtansine (Kadcyla®) with or without pertuzumab versus trastuzumab 
plus taxane for human epidermal growth factor receptor 2–positive, advanced breast 
cancer 
Relevant 
8. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes Relevant 
9. Rucaparib (Rubraca®) in relapsed, platinum-sensitive high-grade ovarian carcinoma Relevant 
10. Niraparib (MK-4827) maintenance therapy in platinum sensitive, recurrent ovarian 
cancer 
Relevant 
11. Prolonged survival in stage III melanoma with ipilimumab (Yervoy®) adjuvant therapy Highly 
relevant 
12. Regorafenib (Stivarga®) for patients with hepatocellular carcinoma who progressed on 
sorafenib treatment Relevant 
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1 Lung cancer 
1.1 Atezolizumab (Tecentriq®) versus docetaxel in patients with 
previously treated non-small-cell lung cancer  
Overview 
Drug Description a programmed death-ligand 1 (PD-L1) blocking antibody 
Patient Indication atezolizumab for previously treated non-small-cell lung cancer 
Incidence in 
Austria 
4,716 newly diagnosed per year (2014), 56.9/100,000/year (European 
Standard Population, 2013) 
Ongoing Phase III NCT01903993 until 02/2017 NCT02008227 until 12/2017 
Approval 
status for 
this 
indication 
EMA - 
FDA 10/2016: metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy 
Approval 
status for 
other 
indications 
EMA - 
FDA 
05/2016: for the treatment of patients with locally advanced or metastatic 
urothelial carcinoma who: 
• have disease progression during or following platinum-containing 
chemotherapy 
• have disease progression within 12 months of neoadjuvant or adjuvant 
treatment with platinum-containing chemotherapy 
Costs  - 
 
Phase III results  
Lancet (2017), published online December 12, 2016 (Rittmeyer et al.) “Atezolizumab versus 
docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, 
multicentre randomised controlled trial” 
 
Background 
Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that 
inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating 
anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated 
patients with non-small-cell lung cancer. 
 
Methods 
We did a randomised, open-label, phase 3 trial (OAK) in 194 academic or community oncology 
centres in 31 countries. We enrolled patients who had squamous or non-squamous non-small-cell lung 
cancer, were 18 years or older, had measurable disease per Response Evaluation Criteria in Solid 
Tumors, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients had 
received one to two previous cytotoxic chemotherapy regimens (one or more platinum based 
combination therapies) for stage IIIB or IV non-small-cell lung cancer. Patients with a history of 
autoimmune disease and those who had received previous treatments with docetaxel, CD137 
agonists, anti-CTLA4, or therapies targeting the PD-L1 and PD-1 pathway were excluded. Patients 
were randomly assigned (1:1) to intravenously receive either atezolizumab 1200 mg or docetaxel 75 
mg/m2 every 3 weeks by permuted block randomisation (block size of eight) via an interactive voice or 
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web response system. Coprimary endpoints were overall survival in the intention-to-treat (ITT) and 
PD-L1-expression population TC1/2/3 or IC1/2/3 (≥1% PD-L1 on tumour cells or tumour-infiltrating 
immune cells). The primary efficacy analysis was done in the first 850 of 1225 enrolled patients. This 
study is registered with ClinicalTrials.gov, number NCT02008227. 
 
Findings 
Between March 11, 2014, and April 29, 2015, 1225 patients were recruited. In the primary population, 
425 patients were randomly assigned to receive atezolizumab and 425 patients were assigned to 
receive docetaxel. Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-
expression populations. In the ITT population, overall survival was improved with atezolizumab 
compared with docetaxel (median overall survival was 13·8 months [95% CI 11·8–15·7] vs 9·6 months 
[8·6–11·2]; hazard ratio [HR] 0·73 [95% CI 0·62–0·87], p=0·0003). Overall survival in the TC1/2/3 or 
IC1/2/3 population was improved with atezolizumab (n=241) compared with docetaxel (n=222; median 
overall survival was 15·7 months [95% CI 12·6–18·0] with atezolizumab vs 10·3 months [8·8–12·0] 
with docetaxel; HR 0·74 [95% CI 0·58–0·93]; p=0·0102). Patients in the PD-L1 low or undetectable 
subgroup (TC0 and IC0) also had improved survival with atezolizumab (median overall survival 12·6 
months vs 8·9 months; HR 0·75 [95% CI 0·59–0·96]). Overall survival improvement was similar in 
patients with squamous (HR 0·73 [95% CI 0·54–0·98]; n=112 in the atezolizumab group and n=110 in 
the docetaxel group) or non-squamous (0·73 [0·60–0·89]; n=313 and n=315) histology. Fewer patients 
had treatment-related grade 3 or 4 adverse events with atezolizumab (90 [15%] of 609 patients) 
versus docetaxel (247 [43%] of 578 patients). One treatment-related death from a respiratory tract 
infection was reported in the docetaxel group. 
 
Interpretation 
To our knowledge, OAK is the first randomised phase 3 study to report results of a PD-L1-targeted 
therapy, with atezolizumab treatment resulting in a clinically relevant improvement of overall survival 
versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expression or 
histology, with a favourable safety profile. 
2 Urothelial carcinoma 
2.1 Pembrolizumab (Keytruda®, MK-3475) as second-line therapy 
for advanced urothelial carcinomas 
Overview 
Drug Description a human programmed death receptor-1 (PD-1)-blocking antibody 
Patient Indication 
pembrolizumab for metastatic or surgically unresectable urothelial 
carcinoma whose disease progressed or recurred despite previous 
treatment with at least one platinum-based chemotherapy regimen 
Incidence in 
Austria 
1,427 newly diagnosed per year (2014), 17.3/100,000/year (European 
Standard Population, 2013) 
Ongoing Phase III NCT02256436 - until 01/2017 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
07/2015: pembrolizumab as monotherapy is indicated for the treatment of 
advanced (unresectable or metastatic) melanoma in adults  
07/2016: pembrolizumab for the treatment of locally advanced or 
metastatic non-small cell lung carcinoma (NSCLC) in adults whose 
tumours express PD-L1 and who have received at least one prior 
chemotherapy regimen. Patients with EGFR or ALK positive tumour 
mutations should also have received approved therapy for these mutations 
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prior to receiving pembrolizumab 
FDA 
09/2014: patients with unresectable or metastatic melanoma and disease 
progression following ipilimumab and, if BRAF V600 mutation positive, a 
BRAF inhibitor 
10/2016:  
• Patients with metastatic NSCLC whose tumors have high PD-L1 
expression (Tumor Proportion Score [TPS] greater than or equal to 
50%) as determined by an FDA-approved test, with no EGFR or ALK 
genomic tumor aberrations, and no prior systemic chemotherapy 
treatment for metastatic NSCLC 
• Patients with metastatic NSCLC whose tumors express PD-L1 (TPS 
greater than or equal to 1%) as determined by an FDA-approved test, 
with disease progression on or after platinum-containing 
chemotherapy. Patients with EGFR or ALK genomic tumor 
aberrations should have disease progression on FDA-approved 
therapy for these aberrations prior to receiving pembrolizumab 
08/2016: for the treatment of patients with recurrent or metastatic head 
and neck squamous cell carcinoma with disease progression on or after 
platinum-containing chemotherapy 
Costs  pembrolizumab 50 mg: € 1,812.55 
- patients received 200 mg every 3 weeks (€7,250.2) 
 
Phase III results  
NEJM (2017), published online February 17, (Bellmunt et al.) “Pembrolizumab as Second-Line 
Therapy for Advanced Urothelial Carcinoma” 
 
Background 
Patients with advanced urothelial carcinoma that progresses after platinum-based chemotherapy have 
a poor prognosis and limited treatment options. 
 
Methods 
In this open-label, international, phase 3 trial, we randomly assigned 542 patients with advanced 
urothelial cancer that recurred or progressed after platinum-based chemotherapy to receive 
pembrolizumab (a highly selective, humanized monoclonal IgG4κ isotype antibody against 
programmed death 1 [PD-1]) at a dose of 200 mg every 3 weeks or the investigator’s choice of 
chemotherapy with paclitaxel, docetaxel, or vinflunine. The coprimary end points were overall survival 
and progression-free survival, which were assessed among all patients and among patients who had a 
tumor PD-1 ligand (PD-L1) combined positive score (the percentage of PD-L1–expressing tumor and 
infiltrating immune cells relative to the total number of tumor cells) of 10% or more. 
 
Results 
The median overall survival in the total population was 10.3 months (95% confidence interval [CI], 8.0 
to 11.8) in the pembrolizumab group, as compared with 7.4 months (95% CI, 6.1 to 8.3) in the 
chemotherapy group (hazard ratio for death, 0.73; 95% CI, 0.59 to 0.91; P=0.002). The median overall 
survival among patients who had a tumor PD-L1 combined positive score of 10% or more was 8.0 
months (95% CI, 5.0 to 12.3) in the pembrolizumab group, as compared with 5.2 months (95% CI, 4.0 
to 7.4) in the chemotherapy group (hazard ratio, 0.57; 95% CI, 0.37 to 0.88; P=0.005). There was no 
significant between-group difference in the duration of progression-free survival in the total population 
(hazard ratio for death or disease progression, 0.98; 95% CI, 0.81 to 1.19; P=0.42) or among patients 
who had a tumor PD-L1 combined positive score of 10% or more (hazard ratio, 0.89; 95% CI, 0.61 to 
1.28; P=0.24). Fewer treatment-related adverse events of any grade were reported in the 
pembrolizumab group than in the chemotherapy group (60.9% vs. 90.2%); there were also fewer 
events of grade 3, 4, or 5 severity reported in the pembrolizumab group than in the chemotherapy 
group (15.0% vs. 49.4%). 
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Conclusion 
Pembrolizumab was associated with significantly longer overall survival (by approximately 3 months) 
and with a lower rate of treatment-related adverse events than chemotherapy as second-line therapy 
for platinum-refractory advanced urothelial carcinoma. (Funded by Merck; KEYNOTE-045 
ClinicalTrials.gov number, NCT02256436.) 
 
3 Multiple Myeloma 
3.1 Daratumumab (Darzalex®), bortezomib, and dexamethasone for 
multiple myeloma 
Overview 
Drug Description human CD38-directed monoclonal antibody (CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface of hematopoietic cells) 
Patient Indication daratumumab in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. 
Incidence in 
Austria 
382 newly diagnosed per year (2014), 4.3/100,000/year (European 
Standard Population, 2013) 
Ongoing Phase III NCT02136134 - until 03/2017 
Approval 
status for 
this 
indication 
EMA - 
FDA 
11/2016: in combination with lenalidomide and dexamethasone, or 
bortezomib and dexamethasone, for the treatment of patients with multiple 
myeloma who have received at least one prior therapy 
Approval 
status for 
other 
indications 
EMA 
05/2016: approved as a monotherapy for the treatment of adult patients 
with relapsed and refractory multiple myeloma, whose prior therapy 
included a proteasome inhibitor and an immunomodulatory agent and who 
have demonstrated disease progression on the last therapy.  
On 17 July 2013, orphan designation was granted by the European 
Commission to Janssen-Cilag International N.V., Belgium, for 
daratumumab for the treatment of plasma-cell myeloma. 
FDA 
11/2015: approved for the administration as a single agent for the 
treatment of patients with multiple myeloma who have received at least 
three prior lines of therapy, including a proteasome inhibitor (PI) and an 
immunomodulatory agent, or who are double-refractory to a PI and an 
immunomodulatory agent.  
Costs  
1 cycle  21 days 
Dexamethasone: in one treatment cycle a dosis of 20 mg was 
administered 8 times  total of 160 mg; 100 mg  €28.70 and for 160 mg 
costs of €45.92 would incur for 1 treatment cycle 
Bortezomib: 1.3 mg/square meter body surface administered 
(subcutaneously) 4 times per treatment cycle; 3.5 mg  €1,218.95 
assuming a body surface of 1.70 m2, 2.21 mg (€769.68) are needed per 
administration and for 1 treatment cycle costs of €3,078.7 would incur 
Daratumumab: 16 mg/kg/once per week (intravenously); 400 mg  
€2,209.45; assuming an average body weight of 70 kg, 1,120 mg are 
needed per week and 3,360 mg are needed for 3 weeks; costs of 
€18,559.38 would incur for 1 treatment cycle  
Total costs of €21,684 for 1 treatment cycle of combination treatment 
would incur 
Ergänzende Informationen zu den Arzneistoffen für Priorisierung XXX – HSS Onkologie Seite 8 von 12 
Phase III results  
NEJM (2016) 375:754-766 (Palumbo et al.): “Daratumumab, Bortezomib, and Dexamethasone for 
Multiple Myeloma” 
 
Background 
Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect 
antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients 
with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed 
multiple myeloma. 
 
Methods 
In this phase 3 trial, we randomly assigned 498 patients with relapsed or relapsed and refractory 
multiple myeloma to receive bortezomib (1.3 mg per square meter of body-surface area) and 
dexamethasone (20 mg) alone (control group) or in combination with daratumumab (16 mg per 
kilogram of body weight) (daratumumab group). The primary end point was progression-free survival. 
 
Results 
A prespecified interim analysis showed that the rate of progression-free survival was significantly 
higher in the daratumumab group than in the control group; the 12-month rate of progression-free 
survival was 60.7% in the daratumumab group versus 26.9% in the control group. After a median 
follow-up period of 7.4 months, the median progression-free survival was not reached in the 
daratumumab group and was 7.2 months in the control group (hazard ratio for progression or death 
with daratumumab vs. control, 0.39; 95% confidence interval, 0.28 to 0.53; P<0.001). The rate of 
overall response was higher in the daratumumab group than in the control group (82.9% vs. 63.2%, 
P<0.001), as were the rates of very good partial response or better (59.2% vs. 29.1%, P<0.001) and 
complete response or better (19.2% vs. 9.0%, P=0.001). Three of the most common grade 3 or 4 
adverse events reported in the daratumumab group and the control group were thrombocytopenia 
(45.3% and 32.9%, respectively), anemia (14.4% and 16.0%, respectively), and neutropenia (12.8% 
and 4.2%, respectively). Infusion-related reactions that were associated with daratumumab treatment 
were reported in 45.3% of the patients in the daratumumab group; these reactions were mostly grade 
1 or 2 (grade 3 in 8.6% of the patients), and in 98.2% of these patients, they occurred during the first 
infusion. 
 
Conclusion 
Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in 
combination with bortezomib and dexamethasone resulted in significantly longer progression-free 
survival than bortezomib and dexamethasone alone and was associated with infusion-related 
reactions and higher rates of thrombocytopenia and neutropenia than bortezomib and dexamethasone 
alone. (Funded by Janssen Research and Development; ClinicalTrials.gov number, NCT02136134.) 
 
3.2 Bortezomib (Velcade®) with lenalidomide and dexamethasone 
versus lenalidomide and dexamethasone alone in patients with 
newly diagnosed myeloma without intent for immediate 
autologous stem-cell transplant 
Overview 
Drug Description a first-in-class proteasome inhibitor 
Patient Indication 
bortezomib with lenalidomide and dexamethasone for untreated multiple 
myeloma who were not planned for immediate 
autologous stem-cell transplant 
Incidence in 
Austria 
382 newly diagnosed per year (2014), 4.3/100,000/year (European 
Standard Population, 2013) 
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Ongoing Phase III NCT02136134 - until 03/2017 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
12/2013: monotherapy or in combination with pegylated liposomal 
doxorubicin or dexamethasone is indicated for the treatment of adult 
patients with progressive multiple myeloma who have received at least 1 
prior therapy and who have already undergone or are unsuitable for 
haematopoietic stem cell transplantation. 
08/2008: in combination with melphalan and prednisone is indicated for 
the treatment of adult patients with previously untreated multiple myeloma 
who are not eligible for high dose chemotherapy with haematopoietic stem 
cell transplantation. 
06/2013: in combination with dexamethasone, or with dexamethasone and 
thalidomide, is indicated for the induction treatment of adult patients with 
previously untreated multiple myeloma who are eligible for high dose 
chemotherapy with haematopoietic stem cell transplantation. 
01/2015: in combination with rituximab, cyclophosphamide, doxorubicin 
and prednisone is indicated for the treatment of adult patients with 
previously untreated mantle cell lymphoma who are unsuitable for 
haematopoietic stem cell transplantation. 
FDA 
06/2003: for the treatment of patients with multiple myeloma 
12/2006: for the treatment of patients with mantle cell lymphoma who have 
received at least one prior therapy. 
Costs  
1 cycle  21 days 
Dexamethasone: in one treatment cycle a dosis of 20 mg was 
administered 8 times  total of 160 mg; 100 mg  €28.70 and for 160 mg 
costs of €45.92 would incur for 1 treatment cycle 
Bortezomib: 1.3 mg/square meter body surface administered 
(subcutaneously) 4 times per treatment cycle; 3.5 mg  €1,218.95 
assuming a body surface of 1.70 m2, 2.21 mg (€769.68) are needed per 
administration and for 1 treatment cycle costs of €3,078.7 would incur 
Lenalidomide: 1 cycle: 25 mg daily on days 1–14; 21 pieces  €6,696.10 
and for 1 treatment cycle (14 pieces) €4,464.1 would incur  
Total costs of €7,588.72 for 1 treatment cycle of combination treatment 
would incur 
 
Phase III results  
Lancet (2016) published online December 22, (Durie et al.): “Bortezomib with lenalidomide and 
dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed 
myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, 
open-label, phase 3 trial” 
 
Background 
Lenalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed 
myeloma. The combination of the proteasome inhibitor bortezomib with lenalidomide and 
dexamethasone has shown significant efficacy in the setting of newly diagnosed myeloma. We aimed 
to study whether the addition of bortezomib to lenalidomide and dexamethasone would improve 
progression-free survival and provide better response rates in patients with previously untreated 
multiple myeloma who were not planned for immediate autologous stem-cell transplant. 
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Methods 
In this randomised, open-label, phase 3 trial, we recruited patients with newly diagnosed multiple 
myeloma aged 18 years and older from participating Southwest Oncology Group (SWOG) and 
National Clinical Trial Network (NCTN) institutions (both inpatient and outpatient settings). Key 
inclusion criteria were presence of CRAB (C=calcium elevation; R=renal impairment; A=anaemia; 
B=bone involvement) criteria with measurable disease (measured by assessment of free light chains), 
Eastern Cooperative Oncology Group (ECOG) performance status of 0–3, haemoglobin concentration 
9 g/dL or higher, absolute neutrophil count 1 × 103 cells per mm3 or higher, and a platelet count of 
80 000/mm3 or higher. We randomly assigned (1:1) patients to receive either an initial treatment of 
bortezomib with lenalidomide and dexamethasone (VRd group) or lenalidomide and dexamethasone 
alone (Rd group). Randomisation was stratified based on International Staging System stage (I, II, or 
III) and intent to transplant (yes vs no). The VRd regimen was given as eight 21-day cycles. 
Bortezomib was given at 1·3 mg/m2 intravenously on days 1, 4, 8, and 11, combined with oral 
lenalidomide 25 mg daily on days 1–14 plus oral dexamethasone 20 mg daily on days 1, 2, 4, 5, 8, 9, 
11, and 12. The Rd regimen was given as six 28-day cycles. The standard Rd regimen consisted of 25 
mg oral lenalidomide once a day for days 1–21 plus 40 mg oral dexamethasone once a day on days 1, 
8, 15, and 22. The primary endpoint was progression-free survival using a prespecified one-sided 
stratified log rank test at a significance level of 0·02. Analyses were intention to treat. This trial is 
registered with ClinicalTrials.gov, number NCT00644228. 
 
Findings 
Between April, 2008, and February, 2012, we randomly assigned 525 patients at 139 participating 
institutions (264 to VRd and 261 to Rd). In the randomly assigned patients, 21 patients in the VRd 
group and 31 in the Rd group were deemed ineligible based mainly on missing, insufficient, or early or 
late baseline laboratory data. Median progression-free survival was significantly improved in the VRd 
group (43 months vs 30 months in the Rd group; stratified hazard ratio [HR] 0·712, 96% CI 0·56–
0·906; one-sided p value 0·0018). The median overall survival was also significantly improved in the 
VRd group (75 months vs 64 months in the Rd group, HR 0·709, 95% CI 0·524–0·959; two-sided p 
value 0·025). The rates of overall response (partial response or better) were 82% (176/216) in the VRd 
group and 72% (153/214) in the Rd group, and 16% (34/216) and 8% (18/214) of patients who were 
assessable for response in these respective groups had a complete response or better. Adverse 
events of grade 3 or higher were reported in 198 (82%) of 241 patients in the VRd group and 169 
(75%) of 226 patients in the Rd group; 55 (23%) and 22 (10%) patients discontinued induction 
treatment because of adverse events, respectively. There were no treatment-related deaths in the Rd 
group, and two in the VRd group. 
 
Interpretation 
In patients with newly diagnosed myeloma, the addition of bortezomib to lenalidomide and 
dexamethasone resulted in significantly improved progression-free and overall survival and had an 
acceptable risk-benefit profile. 
 
4 Skin cancer 
4.1 Prolonged survival in stage III melanoma with ipilimumab 
(Yervoy®) adjuvant therapy 
Overview 
Drug Description a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte 
antigen 4 (CTLA-4) to augment antitumor immune responses 
Patient Indication ipilimumab indicated at a dose of 10 mg per kilogram in patients who had 
undergone complete resection of stage III melanoma 
Incidence in 
Austria 
1,794 newly diagnosed per year (2014), 21.1 /100,000/year (European 
Standard Population, 2013) 
Ongoing Phase III NCT00636168 - until 09/2019 
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Approval 
status for 
this 
indication 
EMA - 
FDA 
10/2015: Approval for the additional indication of adjuvant treatment of 
patients with cutaneous melanoma with pathologic involvement of regional 
lymph nodes of more than 1 mm who have undergone complete resection, 
including total lymphadenectomy 
Approval 
status for 
other 
indications 
EMA 03/2011: Approval for the treatment of unresectable or metastatic 
melanoma in adults who have received prior therapy 
FDA approval status 2011: indicated for the treatment of unresectable or 
metastatic melanoma 
Costs 
YERVOY 
1 cycle  21 days 
The recommended dose-schedule of ipilimumab is 10 mg/kg intravenously 
every 3 weeks for 4 doses, thereafter every 3 months for up to 3 years; 
5mg/ml 10 ml  €4,447.45; assuming an average body weight of 70 kg, a 
dose of 700 mg iplimumab would be needed, costing €62,264.30 per a 3-
week cycle 

Phase III results  
N Engl J Med 2016; 375:1845-1855, (Eggermont et al.) “Prolonged Survival in Stage III Melanoma 
with Ipilimumab Adjuvant Therapy” 
 
Background 
On the basis of data from a phase 2 trial that compared the checkpoint inhibitor ipilimumab at doses of 
0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with advanced melanoma, this phase 
3 trial evaluated ipilimumab at a dose of 10 mg per kilogram in patients who had undergone complete 
resection of stage III melanoma. 
 
Methods 
After patients had undergone complete resection of stage III cutaneous melanoma, we randomly 
assigned them to receive ipilimumab at a dose of 10 mg per kilogram (475 patients) or placebo (476) 
every 3 weeks for four doses, then every 3 months for up to 3 years or until disease recurrence or an 
unacceptable level of toxic effects occurred. Recurrence-free survival was the primary end point. 
Secondary end points included overall survival, distant metastasis–free survival, and safety. 
 
Results 
At a median follow-up of 5.3 years, the 5-year rate of recurrence-free survival was 40.8% in the 
ipilimumab group, as compared with 30.3% in the placebo group (hazard ratio for recurrence or death, 
0.76; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). The rate of overall survival at 5 years was 
65.4% in the ipilimumab group, as compared with 54.4% in the placebo group (hazard ratio for death, 
0.72; 95.1% CI, 0.58 to 0.88; P = 0.001). The rate of distant metastasis–free survival at 5 years was 
48.3% in the ipilimumab group, as compared with 38.9% in the placebo group (hazard ratio for death 
or distant metastasis, 0.76; 95.8% CI, 0.64 to 0.92; P = 0.002). Adverse events of grade 3 or 4 
occurred in 54.1% of the patients in the ipilimumab group and in 26.2% of those in the placebo group. 
Immunerelated adverse events of grade 3 or 4 occurred in 41.6% of the patients in the ipilimumab 
group and in 2.7% of those in the placebo group. In the ipilimumab group, 5 patients (1.1%) died 
owing to immune-related adverse events. 
 
Conclusion 
As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram 
resulted in significantly higher rates of recurrence-free survival, overall survival, and distant 
metastasis–free survival than placebo. There were more immune-related adverse events with 
ipilimumab than with placebo. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, 
NCT00636168, and EudraCT number, 2007-001974-10.) 
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Background 
The EORTC 18071 phase 3 trial compared adjuvant ipilimumab with placebo in patients with stage III 
melanoma. The primary endpoint, recurrence-free survival, was significantly longer in the ipilimumab 
group than in the placebo group. Investigator-reported toxic effects of ipilimumab consisted mainly of 
skin, gastrointestinal, endocrine, and hepatic immune-related adverse events. Adjuvant treatment with 
ipilimumab in this setting was approved in October, 2014, by the US Food and Drug Administration 
based on the results of the primary outcome of this trial. Here, we report the results of the secondary 
endpoint, health-related quality of life (HRQoL), of this trial. 
 
Methods: 
EORTC 18071 was a multinational, double-blind, randomised, phase 3 trial in patients with stage III 
cutaneous melanoma (excluding lymph node metastasis ≤1 mm or in-transit metastasis) in 19 
countries worldwide. Participants were randomly assigned (1:1) centrally by an interactive voice 
response system, to receive either ipilimumab 10 mg/kg or placebo every 3 weeks for four doses, then 
every 3 months for up to 3 years. Using a minimisation technique, randomisation was stratified by 
disease stage and geographical region. HRQoL was assessed with the EORTC QLQ-C30 quality-of-
life instrument at baseline, weeks 4, 7, 10, and 24, and every 12 weeks thereafter up to 2 years, 
irrespective of disease progression. Results were summarised by time-point and in a longitudinal 
manner in the intention-to-treat population. Two summary scores were calculated for each HRQoL 
scale: the average score reported during induction (ipilimumab or placebo at a dose of 10 mg/kg, 
administered as one single dose at the start of days 1, 22, 43, and 64—ie, four doses in 3 weeks), and 
the average score reported after induction. A predefined threshold of a 10 point difference between 
arms was considered clinically relevant. The primary HRQoL endpoint was the global health scale, 
with the predefined hypothesis of no clinically relevant differences after induction between groups. 
This trial is registered with EudraCT, number 2007-001974-10, and ClinicalTrials.gov, number 
NCT00636168. 
 
Findings 
Between July 10, 2008, and Aug 1, 2011, 951 patients were randomly assigned to treatment: 475 in 
the ipilimumab group and 476 in the placebo group. Compliance with completing the HRQoL 
questionnaire was 893 (94%) of 951 patients at baseline, 693 (75%) of 924 at week 24, and 354 
(51%) of 697 at week 108. Patient mean global health scores during (77.32 [SD 17.36] vs 72.96 
[17.82]; p=0.00011) and after induction (76.48 [17.52] vs 72.32 [18.60]; p=0.00067) were statistically 
significantly different between groups but were not clinically relevant. Mean global health scores 
differed most between the groups at week 7 (77 [SD 19] in the placebo group vs 72 [22] in the 
ipilimumab group) and week 10 (77 [20] vs 70 [23]). Mean HRQoL scores differed by more than 10 
points at week 10 between treatment groups for diarrhoea (7.67 [SD 17.05] for placebo vs 18.17 
[28.35] for ipilimumab) and insomnia (15.17 [22.53] vs 25.60 [29.19]). 
 
Interpretation 
Despite increased toxicity, which led to treatment discontinuation for most patients during the induction 
phase of ipilimumab administration, overall HRQoL, as measured by the EORTC QLQ-C30, was 
similar between groups, as no clinically relevant differences (10 points or more) in global health status 
scores were observed during or after induction. Clinically relevant deterioration for some symptoms 
was observed at week 10, but after induction, no clinically relevant differences remained. Together 
with the primary analysis, results from this trial show that treatment with ipilimumab results in longer 
recurrence-free survival compared with that for treatment with placebo, with little impairment in HRQoL 
despite grade 3–4 investigator-reported adverse events. 
 
